Clinical Trial Update: Bioavailability of ABT-333 Tablet Versus First in Human (FIH) Capsule Formulation and Safety, Tolerability and PK Study of Single Doses of ABT-333 in Healthy Volunteers [Phase 1]

View source ↗

Summary

Phase 1 study comparing ABT-333 tablet to the first-in-human capsule, examining bioavailability and assessing safety, tolerability, and single-dose pharmacokine…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• ABT-333 (ABT-333)

Snippet

Sponsor: Abbott | Conditions: HCV Infection | Phase 1 | Status: COMPLETED